Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
Dr. Dere brings to Mersana more than three decades of research, clinical and regulatory biopharmaceutical leadership experience. He is currently Professor of Internal Medicine, Executive Director of Personalized Health, and Co-director of the Center for Clinical and Translational Sciences at the University of Utah Health Sciences Center. Dr. Dere also spent twenty-five years in leadership positions at
"As we advance our two novel clinical oncology programs, continue to grow our pipeline and expand our platform, Will’s broad R&D experience will be an invaluable resource for Mersana,” said Anna Protopapas, President and Chief Executive Officer of Mersana. "We are delighted to welcome Will to our board and know that Mersana will benefit enormously from his comprehensive research and clinical development experience.”
"I am very excited for the opportunity to join the Mersana Board and work closely with the management team to help the Company fulfill its mission of delivering transformative therapies to cancer patients," said Dr. Dere. "The Mersana team has rapidly progressed their novel ADC-based programs, which have shown tremendous potential, and taken significant steps towards executing on their promise to create clinically meaningful therapies for cancer patients.”
Biographical Background
Dr. Dere serves as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for
About
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements generally can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials and that the development of the Company’s product candidates will take longer and/or cost more than planned, as well as those listed in the Company’s Quarterly Report on Form 10-Q filed on
Copies of the Company’s our Quarterly Report on Form 10-Q and our other SEC filings are available by visiting EDGAR on the SEC website at http://www.sec.gov.
Contacts:
Media Contact
paulkidwell@mersana.com
or
Investors Contact
Stern Investor Relations, Inc.
christina@sternir.com
Source: Mersana Therapeutics, Inc.